Estradiol

Synonyms: D-Estradiol, D-Oestradiol, Estradiol-17beta, Estradiol Valerate, Estradiol Cypionate, Dihydroxyestrin, Dihydroxyoestrin, Dihydroxyesterin, Dihydrofollicular Hormone, Dihydrofolliculin, Cis-Estradiol, Cis-Oestradiol, Beta-Estradiol, estradiol, 17-beta.

Brand Names: Aerodiol, Agofollin, Alora, Altrad, Amnestrogen, Aquadiol, Bardiol, Climaderm, Climara, Combipatch, Compudose, Compudose 200, Compudose 365, Corpagen, Delestrogen, Depo-Estradiol, Dermestril, Dihydromenformon, Dihydrotheelin, Dimenformon, Dimenformon Prolongatum, Diogyn, Diogynets, Divigel, Encore, Esclim, Estinyl, Estrace, Estraderm, Estraderm Tts, Estradurin, Estrasorb, Estreva, Estrifam, Estring, Estring Vaginal Ring, Estroclim, Estroclim 50, Estrofem 2, Estrofem Forte, Estrogel, Estrogens, Esterified, Estrovite, Evorel, Extrasorb, Femestral, Femestrol, Feminone, Femogen, Fempatch, Femring, Femtrace, Femtran, Follicyclin, Ginedisc, Ginosedol, Gynergon, Gynestrel, Gynodiol, Gynoestryl, Gynpolar, Innofem, Lamdiol, Lynoral, Macrodiol, Macrol, Menest, Menorest, Menostar, Microdiol, Nordicol, Oestergon, Oestradiol, Oestradiol R, Oestrogel, Oestroglandol, Oestrogynal, Ovahormon, Ovasterol, Ovastevol, Ovociclina, Ovocyclin, Ovocycline, Ovocylin, Perlatanol, Primofol, Profoliol, Profoliol B, Progynon, Progynon Dh, Progynon-Dh, Ricifon, Ritsifon, Sandrena Gel, Sisare Gel, Sk-Estrogens, Soldep, Sotipox, Syndiol, Systen, Tradelia, Trial Sat, Trocosone, Vagifem, Vivelle, Zerella, Zumenon, Elestrin, Evamist.

Dosing and Administration
When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding. Patients should be started at the lowest dose for the indication. 1. For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible. Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage range is 1 to 2 mg daily of Estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off). 2. For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. Treatment is usually initiated with a dose of 1 to 2 mg daily of Estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration. 3. For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease. Suggested dosage is 10 mg three times daily for a period of at least three months. 4. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only. Suggested dosage is 1 to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient. 5. For prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should be considered only for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The lowest effective dose of Estradiol has not been determined.

FDA Package Insert Resources Indications, Contraindications, Side Effects, Drug Interactions, etc. Calculate Creatine Clearance On line calculator of your patients Cr Cl by a variety of formulas. Convert pounds to Kilograms On line calculator of your patients weight in pounds to Kg for dosing estimates. Publication Resources Recent articles, WikiDoc State of the Art Review, Textbook Information Trial Resources Ongoing Trials, Trial Results Guidelines & Evidence Based Medicine Resources US National Guidelines, Cochrane Collaboration, etc. Media Resources Slides, Video, Images, MP3, Podcasts, etc. Patient Resources Discussion Groups, Handouts, Blogs, News, etc. International Resources en Español

FDA Package Insert Resources
Indications Contraindications Side Effects Drug Interactions Precautions Overdose Instructions for Administration How Supplied Pharmacokinetics and Molecular Data FDA label FDA on Return to top

Publication Resources
Most Recent Articles on Review Articles on Articles on in N Eng J Med, Lancet, BMJ WikiDoc State of the Art Review Textbook Information on Return to top

Trial Resources
Ongoing Trials with at Clinical Trials.gov Trial Results with Return to top

Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Cochrane Collaboration on Cost Effectiveness of Return to top

Media Resources
Powerpoint Slides on Images of Podcasts & MP3s on Videos on Return to top

Patient Resources
Patient Information from National Library of Medicine Patient Resources on Discussion Groups on Patient Handouts on Blogs on in the News in the Marketplace Return to top

International Resources
en Español Return to top